
The main point about excess in the pharmaceutical industry is how much there is of it. Here I can touch on only a few specifics about this altogether over-the-top business. ![Figure][1] Figure. Photo by: Earthlore Although the pharmaceutical industry claims to be a high-risk business,
Marketing, Drug Industry, Lobbying, Therapeutic Equivalency, Government, Physicians, Commerce, Drug Costs, United States
Marketing, Drug Industry, Lobbying, Therapeutic Equivalency, Government, Physicians, Commerce, Drug Costs, United States
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 111 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
